Appointment of Director

Bioventix plc ("Bioventix" or the "Company") Appointment of Director Bioventix plc (ISDX: BVXP) is delighted to announce the appointment of Nick McCooke as a Non-Executive Director. Mr. McCooke has worked in the biotech industry for over 25 years and is now an independent consultant providing operational, strategic and commercial advice and hands-on support to biotech companies. He was the founding Chief Executive Officer of Solexa, a Cambridge University spin-out where he built the team that invented and developed Next Generation DNA Sequencing. More recently he was CEO of the Belgian company Pronota, which is translating novel protein biomarkers into diagnostics. He has an MBA from the London Business School. "We are delighted to welcome Nick McCooke to Bioventix", said Peter Harrison. "His experience in building successful biotech companies is well established and his appointment is a welcome addition at this stage of Bioventix's development". Further information on Nicholas McCooke: Director/partner positions currently Director/partner positions held in held: the past 5 years: none Oxford Cancer Biomarkers Limited For further information please contact: Bioventix plc Peter Harrison Chief Executive Officer Tel: 01252 728 001 finnCap Ltd Geoff Nash/Simon Hicks Corporate Finance Tel: 020 7220 0500 Steve Norcross Corporate Broking About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares (BVXP) were admitted to trading on PLUS-SX in April 2010.